Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan,
Am J Nephrol. 2020;51(2):160-167. doi: 10.1159/000505718. Epub 2020 Jan 22.
Patients with permanent postsurgical hypoparathyroidism, a complication of total thyroidectomy, often require high calcium supplementation with vitamin D to maintain serum calcium levels. The epidemiology of calcium-alkali syndrome (CAS) in patients with hypoparathyroidism after total thyroidectomy remains unclear. This study aimed to investigate the incidence of hypercalcemia, renal impairment, metabolic alkalosis, and CAS in patients treated for presumed hypoparathyroidism after total thyroidectomy.
Twenty-seven patients with neck cancers who underwent total thyroidectomy without parathyroid autotransplantation between January 2010 and October 2013 at our hospital were consecutively included. All patients received calcium lactate and alfacalcidol for postsurgical hypocalcemia. We defined hypercalcemia as a corrected serum calcium level (cCa) ≥10.5 mg/dL, metabolic alkalosis as a difference in serum sodium and serum chloride ([sNa-sCl]) ≥39 mEq/L, and renal impairment as a ≥50% increase in serum creatine and/or ≥35% decrease in estimated glomerular filtration rate (eGFR) compared to baseline.
cCa peaked (11.1 ± 1.5 mg/dL) at a median of 326 days (interquartile range 78-869) after surgery. At peak cCa, [sNa-sCl] was significantly higher (p < 0.01), and eGFR was significantly lower (p < 0.01) than that at baseline. Fifteen patients (55.6%) had hypercalcemia, 19 (70.3%) had alkalosis, 12 (44.4%) had renal impairment, and 9 (33.3%) had CAS. Patients with CAS (mean age 67.1 ± 10.8 years) were older than those without CAS (56.7 ± 13.6 years, p = 0.06). The mean dose of alfacalcidol in the CAS group (3.1 ± 1.2 μg/day) was significantly larger than that in the non-CAS group (2.1 ± 1.0 μg/day, p = 0.03).
This retrospective study reveals the high incidence of CAS in patients with hypoparathyroidism after total thyroidectomy. Furthermore, these findings suggest that the serum calcium level, acid-base balance, and renal function should be closely monitored in patients with postsurgical hypoparathyroidism who receive large doses of active vitamin D.
甲状旁腺功能减退症是甲状腺全切除术后的一种常见并发症,永久性甲状旁腺功能减退症患者常需要高钙补充和维生素 D 以维持血清钙水平。甲状腺全切除术后甲状旁腺功能减退症患者并发钙-碱综合征(CAS)的流行病学仍不清楚。本研究旨在探讨拟诊甲状旁腺功能减退症患者在甲状腺全切除术后发生高钙血症、肾功能损害、代谢性碱中毒和 CAS 的发生率。
2010 年 1 月至 2013 年 10 月,我院连续纳入 27 例接受甲状腺全切除术(无甲状旁腺自体移植)的颈部癌症患者。所有患者均接受乳酸钙和阿尔法骨化醇治疗术后低钙血症。我们将血清钙校正值(cCa)≥10.5mg/dL 定义为高钙血症,血清钠和血清氯差值([sNa-sCl])≥39mEq/L 定义为代谢性碱中毒,血清肌酐较基线升高≥50%和/或估算肾小球滤过率(eGFR)较基线下降≥35%定义为肾功能损害。
cCa 在术后中位数 326 天(四分位距 78-869)达到峰值(11.1±1.5mg/dL)。在 cCa 峰值时,[sNa-sCl]明显升高(p<0.01),eGFR明显降低(p<0.01)。15 例患者(55.6%)出现高钙血症,19 例(70.3%)出现碱中毒,12 例(44.4%)出现肾功能损害,9 例(33.3%)出现 CAS。CAS 组(平均年龄 67.1±10.8 岁)患者比非 CAS 组(56.7±13.6 岁,p=0.06)年龄更大。CAS 组患者的阿尔法骨化醇剂量(3.1±1.2μg/天)明显大于非 CAS 组(2.1±1.0μg/天,p=0.03)。
本回顾性研究揭示了甲状腺全切除术后甲状旁腺功能减退症患者 CAS 的高发生率。此外,这些发现提示在接受大剂量活性维生素 D 治疗的甲状腺全切除术后甲状旁腺功能减退症患者中,应密切监测血清钙水平、酸碱平衡和肾功能。